Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.

    Semin Nucl Med. 2004 Jan;34(1):S2-3

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

    Semin Nucl Med. 2004 Jan;34(1):S4-9

Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

    Semin Nucl Med. 2004 Jan;34(1):S10-3

Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

    Semin Nucl Med. 2004 Jan;34(1):S14-9

Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).

    Semin Nucl Med. 2004 Jan;34(1):S20-3